Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of chitosan as adjuvant in preparation of influenza virus attenuated live vaccine

A technology for live attenuated vaccines and influenza viruses, which can be used in antiviral agents, medical preparations containing active ingredients, medical components of antibodies, etc. The effect of expanding the immunized population

Inactive Publication Date: 2012-12-19
SHANGHAI INST OF BIOLOGICAL PROD CO LTD
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with inactivated vaccines, the optimal pH value of live attenuated influenza virus vaccines is 4-5, and the relevant conditions such as the concentration of chitosan solution need to be adjusted to ensure the activity of the vaccine. Changes in subtle conditions may cause inactivation of live vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chitosan as adjuvant in preparation of influenza virus attenuated live vaccine
  • Application of chitosan as adjuvant in preparation of influenza virus attenuated live vaccine
  • Application of chitosan as adjuvant in preparation of influenza virus attenuated live vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] One: the preparation of chitosan solution:

[0024] Weigh 3.38g of sodium glutamate and dissolve it in 100ml of water to prepare a 0.2mol sodium glutamate solution. The pH of the solution was adjusted to 2-3 with acetic acid. Weigh 0.4g chitosan into the solution and stir until completely dissolved. The pH value of the solution was adjusted to 4-5 with sodium hydroxide, sterilized by filtration with a 0.22 nm filter membrane, and stored at 4°C in aliquots for later use.

[0025] Two: the preparation of influenza virus attenuated live vaccine:

[0026] Extract virus RNA from the allantoic fluid of chicken embryos inoculated with A / Puerto Rico / 8 / 34 (H1N1) virus, use RT-PCR technology to prepare cDNA, and amplify PB2, PB1, PA, HA, NP of influenza virus , NA, M, NS eight gene segments. Mutations were introduced in PB1 (K391E, E581G, A661T) and PB2 (N265S) by overlapping PCR. BbM I digestion PCR fragment and Phw2000 plasmid, T4 DNA ligase connection. With the help of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of chitosan in preparation of influenza virus attenuated live vaccines, and provides an adjuvant which can reduce the using amount of the influenza virus attenuated live vaccine. According to the invention, chitosan is adopted as an influenza virus attenuated live vaccine adjuvant for the first time, which enhances the immunogenicity of the vaccine, induces human body to generate stronger immune response, effectively reduces the using amount of the vaccine, effectively enlarges immunization population within existing production capacity and technology, and has important social meaning and application value for pandemic influenza.

Description

technical field [0001] The invention relates to the field of biological products, and more specifically relates to an adjuvant capable of reducing the dosage of live attenuated influenza virus vaccines. Background technique [0002] Influenza virus (influenza virus) is a common acute respiratory infectious disease, prone to antigenic drift and antigenic shift, and highly contagious, seriously endangering human health and life. Vaccination is one of the most effective ways to prevent influenza virus infection. However, current influenza vaccine production capacity and technologies are limited. During the 2009-2010 influenza A H1N1 pandemic, as of November 2010, 77 countries in the world had received only 78 million vaccines, and all of them were It was delivered after the second wave of influenza, which is far from enough to meet human demand. Adjuvants can improve the immune response level of vaccines and reduce the dosage of vaccines. The use of adjuvants in vaccines may...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61P31/16A61K39/145
Inventor 陈则
Owner SHANGHAI INST OF BIOLOGICAL PROD CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com